Fortis-TotipotentRX Centre for Cellular Medicine hosted the first annual Symposium on Haploidentical Stem Cell Transplantation in Gurgaon today. The symposium brought national and international experts in the field of paediatrics and haematology/oncology under the same roof to discuss current protocols and challenges for immune oncology therapeutic approaches using bone marrow from a Human Leukocyte Antigen (HLA) disparate related donor.
In this academic symposium, panel discussions were held to provide insight into the latest clinical data to highlight the benefits of this treatment option in the current health care scenario.
According to experts, hematopoietic (stem cells that give rise to all the other blood cells) transplantation is the treatment of choice for patients with bone marrow failure syndrome or advanced hematologic (blood related) malignancies.
However, approximately 70% of patients do not have a matched related donor available for transplantation. For these patients, a matched unrelated donor (MUD) transplant is preferred, due to similar transplant outcomes. The recent medical advances have made a transplant possible from a partially matched or haploidentical related donor. A haploidentical related donor is usually a 50% match to the recipient. This increases the chance of finding a donor. With improvement in medical treatment, the complications from a haploidentical transplant, such as Graft versus Host disease (GVHD), rejection of graft and slow recovery of immune system seem to be minimal.
For more information, please contact:
Ajey Maharaj: +91 9871798573
Tituraj Kashyap Das: +91 9871918187
Tanushree Roy Choudhury: +91 9999425750
Rishu Singh: +91 9958891501
Neeraj Shorya: +91 9911856010
Read Complete Press Release on below link:
Download Pdf - English